Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Spur Therapeutics logo — Toward the next generation of gene therapy.

Spur Therapeutics

Toward the next generation of gene therapy.

Founded 2015 United Kingdom Stevenage, United Kingdom 122 employees Post Ipo Equity Total: $260.50M Biopharma, Biotechnology +3

General Information

Company Name Spur Therapeutics
Founded Year 2015
Location United Kingdom Stevenage, United Kingdom +3
Employees 122
Industries Biopharma, Biotechnology, Health Care +2
Funding Stage Post Ipo Equity
Social

Get notified when Spur Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Spur Therapeutics

Freeline is a biopharmaceutical company focused on developing liver-directed gene therapies for inherited systemic diseases. With clinical programs for Hemophilia B and Fabry disease, and preclinical programs in Gaucher disease and haemophilia A, the company aims to revolutionize treatment options for individuals suffering from debilitating inherited diseases. Founded in 2015, Freeline is based in the United Kingdom, with additional locations in the United States and Germany. The company recently received a notable $26.10M post-IPO equity investment on 10 March 2022, with Syncona Investment Management as the investors. This significant funding reflects investor confidence in Freeline's innovative approach to gene therapy, positioning the company for further growth and impact in the biopharma, biotechnology, and life sciences industries.

Taxonomy: gene therapy, liver-directed, inherited diseases, clinical trials, AAV-based therapy, Hemophilia B, Fabry disease, Gaucher disease, haemophilia A, innovation, global locations, systemic diseases, United Kingdom, United States

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 1
Investor
10 Mar 2022
Series C •••••• 6
Investor Investor Investor Investor Investor Investor
30 Jun 2020
Series C •••••• 1
Investor
19 Dec 2019
Grant •••••• 1
Investor
24 May 2019
Series B •••••• 2
Investor Investor
20 Jun 2018

View All 7 Funding Rounds

Spur Therapeutics Alternatives & Competitors

Spur Therapeutics vs
Taysha Gene Therapies
Taysha Gene Therapies United States

Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases...

IPO
134 employees
Biotechnology, Life Sciences
Compare Spur Therapeutics vs Taysha Gene Therapies
Spur Therapeutics vs
Eikonoklastes Therapeutics, Inc.
Eikonoklastes Therapeutics, Inc.

https://www.eikonoklastes.com/

Series A
8 employees
Biopharma, Biotechnology
Compare Spur Therapeutics vs Eikonoklastes Therapeutics, Inc.
Spur Therapeutics vs
Helixmith
Helixmith Korea South

Regenerative Medicine for Neuropathic, Neuromuscular and Neuroischemic Diseases Using a Gene Therapy...

34 employees
Biopharma, Biotechnology
Compare Spur Therapeutics vs Helixmith
Also compare with: Spur Therapeutics vs Abeona Therapeutics Abeona Therapeutics

FAQ About Spur Therapeutics

Toward the next generation of gene therapy.
Spur Therapeutics was founded in 2015.
Spur Therapeutics is headquartered in Stevenage, United Kingdom.
Spur Therapeutics operates in the following industries: Biopharma, Biotechnology, Health Care, Health and Wellness, Life Sciences.
Spur Therapeutics has approximately 122 employees.
Spur Therapeutics has completed 7 funding rounds, raising a total of $260.50M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Spur Therapeutics include Taysha Gene Therapies, Eikonoklastes Therapeutics, Inc., Helixmith, Abeona Therapeutics, Rejuvenate Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Spur Therapeutics and Taysha Gene Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Spur Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy